Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)

Summary

Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory response, as measured by the area-under-the-curve for C reactive protein over 14 days.

Timeline

Start

2014-02

Primary completion

2015-05

Completion

2015-05

Drugs

Indications